Society for Clinical Research Sites Welcomes New Global Impact Partner
ELLICOTT CITY, Md., March 30, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year partnership with PRA Health Sciences (PRA), a leading CRO. PRA will participate as a Global Impact Partner (GIP), a relationship which exemplifies PRA’s commitment to promoting greater site sustainability for clinical research sites globally.
“PRA’s commitment to become a GIP is indicative of their eagerness to initiate and maintain positive site relationships; we are pleased they have selected SCRS as the catalyst,” commented Christine Pierre, SCRS President. “Collaboration with PRA is a significant strategic development for SCRS, and we are proud to welcome them as our newest GIP.”
“PRA is excited to join SCRS as a Global Impact Partner,” said Michael Brooks, PRA Senior Vice President and Head, Product Registration Americas. “PRA looks forward to maintaining a close engagement with the clinical research site community and, in partnership with SCRS, developing innovations and best practices to accelerate the development of new therapies for patients around the world.”
As a Global Impact Partner (GIP), PRA Health Sciences will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council in the development and execution of strategic initiatives for SCRS.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
